Want to see SBC full AI Analyst Report?
Top Page
SBC Medical Group Holdings
(NASDAQ:SBC)
Select Model
Select Model
Rating:66Neutral
Price Target:
$3.50
▼(-21.70% Downside)
Action:Reiterated
Date:05/14/26
The score is supported primarily by strong financial quality (high profitability/ROE and low leverage) and a low P/E valuation, but is held back by weak technicals (price below key moving averages with negative MACD) and near-term fundamental pressure highlighted by contracting revenue and weaker Q1 2026 earnings.
Positive Factors
High margins and strong ROE
SBC’s very high gross and net margins with ~21% TTM ROE reflect durable pricing power and operating efficiency in aesthetic services. These structural profitability characteristics support reinvestment, franchise backing and the ability to sustain returns through industry cycles.
Negative Factors
Revenue decline and margin compression from fee reform
An April 2025 structural franchise-fee change materially reduced reported revenue and margins, producing a sustained hit to top-line take rates. Because this is a structural contract model shift, it can have lasting negative effects on unit economics, growth trajectory and earnings durability.
Read all positive and negative factors
Positive Factors
Negative Factors
High margins and strong ROE
SBC’s very high gross and net margins with ~21% TTM ROE reflect durable pricing power and operating efficiency in aesthetic services. These structural profitability characteristics support reinvestment, franchise backing and the ability to sustain returns through industry cycles.
Read all positive factors
SBC Medical Group Holdings (SBC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$334.25M
Dividend YieldN/A
Average Volume (3M)65.67K
Price to Earnings (P/E)8.3
Beta (1Y)0.67
Revenue Growth16.92%
EPS Growth63.88%
CountryUS
Employees863
SectorIndustrials
Sector Strength72
IndustryConsulting Services
Share Statistics
EPS (TTM)0.39
Shares Outstanding102,846,950
10 Day Avg. Volume48,167
30 Day Avg. Volume65,672
Financial Highlights & Ratios
PEG Ratio2.07
Price to Book (P/B)1.79
Price to Sales (P/S)2.56
P/FCF Ratio12.15
Enterprise Value/Market Cap0.58
Enterprise Value/Revenue1.14
Enterprise Value/Gross Profit1.62
Enterprise Value/Ebitda2.67
Forecast
1Y Price Target
$8.50Price Target Upside90.16% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.46
Revenue Forecast (FY)$181.04M
SBC Medical Group Holdings Business Overview & Revenue Model
Company Description
SBC Medical Group Holdings Incorporated provides comprehensive operational support to aesthetic and cosmetic clinics across a global footprint, including Japan, Vietnam, the United States, and other international markets. The company delivers a di...
How the Company Makes Money
SBC primarily makes money through fees and revenues tied to the delivery of aesthetic/elective medical services and the management/support of affiliated clinics. Key revenue streams generally include (1) patient-service revenue generated when trea...
SBC Medical Group Holdings Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
86
Very Positive
Cash Flow
74
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 169.34M | 173.61M | 205.42M | 193.54M | 174.16M |
| Gross Profit | 118.88M | 127.28M | 156.05M | 137.30M | 114.83M |
| EBITDA | 72.43M | 84.91M | 77.28M | 85.87M | 29.64M |
| Net Income | 40.79M | 50.99M | 46.61M | 39.37M | 6.32M |
Balance Sheet | |||||
| Total Assets | 388.02M | 380.45M | 266.08M | 258.81M | 225.48M |
| Cash, Cash Equivalents and Short-Term Investments | 167.31M | 164.09M | 125.04M | 103.02M | 53.64M |
| Total Debt | 51.90M | 51.64M | 12.21M | 22.87M | 16.13M |
| Total Liabilities | 117.64M | 117.14M | 71.06M | 115.00M | 117.63M |
| Stockholders Equity | 255.34M | 248.28M | 195.11M | 142.16M | 105.25M |
Cash Flow | |||||
| Free Cash Flow | 44.06M | 36.55M | 17.17M | 39.44M | -24.99M |
| Operating Cash Flow | 46.22M | 38.92M | 20.58M | 50.64M | -47.37K |
| Investing Cash Flow | -20.52M | -20.97M | -10.10M | 1.82M | -32.65M |
| Financing Cash Flow | 22.48M | 24.04M | 22.97M | 6.14M | -7.98M |
SBC Medical Group Holdings Technical Analysis
Positive
4.47
Price Trends
3.14
Positive
3.60
Negative
3.82
Negative
Market Momentum
<0.01
Negative
56.13
Neutral
59.69
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SBC, the sentiment is Positive. The current price of 4.47 is above the 20-day moving average (MA) of 3.05, above the 50-day MA of 3.14, and above the 200-day MA of 3.82, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 56.13 is Neutral, neither overbought nor oversold. The STOCH value of 59.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SBC.
SBC Medical Group Holdings Risk Analysis
SBC Medical Group Holdings disclosed 78 risk factors in its most recent earnings report. SBC Medical Group Holdings reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
SBC Medical Group Holdings Peers Comparison
UnderperformOutperform
Sector (63)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | $334.25M | 8.25 | 16.38% | ― | 16.92% | 63.88% | |
63 Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% | |
60 Neutral | $948.71M | 20.16 | 23.64% | 0.97% | 10.50% | -3.09% | |
55 Neutral | $245.51M | 121.00 | -4.11% | ― | -6.14% | -78.29% | |
52 Neutral | $42.13M | 15.70 | -89.26% | ― | -0.26% | ― | |
50 Neutral | $158.60M | -1.56 | -49.24% | 6.74% | -13.38% | 9.50% | |
48 Neutral | $183.44M | -3.35 | -39.22% | ― | -7.06% | 38.03% |
* Industrials Sector Average
SBC
SBC Medical Group Holdings
3.25
-1.22
-27.29%
CRAI
Cra International
146.79
-47.68
-24.52%
FORR
Forrester Research
9.45
-1.38
-12.74%
FC
Franklin Covey Company
21.78
-0.32
-1.45%
RGP
Resources Connection
4.62
-1.04
-18.37%
AERT
Aeries Technology
7.34
-1.70
-18.81%
SBC Medical Group Holdings Corporate Events
Executive/Board ChangesRegulatory Filings and ComplianceShareholder Meetings
SBC Medical Announces Director Exit and Governance Transition
Neutral
May 20, 2026
On May 14, 2026, SBC Medical Group Holdings said independent director Mike Sayama will not seek re-election at its upcoming 2026 Annual Meeting of Stockholders, clarifying that his decision did not stem from any disagreement with the company, mana...
Business Operations and StrategyFinancial Disclosures
SBC Medical Reports Weaker Q1 2026 Results, Outlines Growth
Negative
May 14, 2026
On May 14, 2026, SBC Medical Group Holdings reported first-quarter 2026 results showing $43 million in revenue, down 9% year over year, and net income of $11 million, a 47% decline with margin compressed to 26%. EBITDA fell 26% to $18 million with...
Business Operations and StrategyPrivate Placements and Financing
SBC Medical Group Announces CEO Secondary Share Offering
Neutral
Apr 23, 2026
On April 19, 2026, SBC Medical Group Holdings Incorporated entered into an underwriting agreement with Maxim Group LLC for a secondary offering of 3,100,000 shares of its common stock held by CEO and chairman Dr. Yoshiyuki Aikawa, with underwriter...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.